GATA binding protein 2 overexpression is associated with poor prognosis in KRAS mutant colorectal cancer

Xu,Kai; Wang,Jiayuan; Gao,Jing; Di,Jiabo; Jiang,Beihai; Chen,Lei; Wang,Zaozao; Wang,Aidong; Wu,Fan; Wu,Wei; Shen,Lin; Su,Xiangqian

doi:10.3892/or.2016.4961

GATA binding protein 2 overexpression is associated with poor prognosis in KRAS mutant colorectal cancer

Authors:
- Kai Xu
- Jiayuan Wang
- Jing Gao
- Jiabo Di
- Beihai Jiang
- Lei Chen
- Zaozao Wang
- Aidong Wang
- Fan Wu
- Wei Wu
- Lin Shen
- Xiangqian Su
View Affiliations

Affiliations: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Surgery IV, Peking University Cancer Hospital and Institute, Beijing 100142, P.R. China, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing 100142, P.R. China
Published online on: July 21, 2016 https://doi.org/10.3892/or.2016.4961
Pages: 1672-1678

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Colorectal cancer (CRC) is one of the most lethal cancers worldwide. Mutations in KRAS occur with the frequency of 30-50% in CRC leading to decreased therapeutic response to anti-epidermal growth factor receptor (EGFR) agents. Recently GATA2 was proven to be essential in the survival of KRAS mutant non-small cell lung cancer (NSCLC) cells. However, the association between KRAS mutation and GATA2 expression in CRC remains largely unknown. In the present study, dideoxy sequencing and immunohistochemistry were used to determine KRAS mutation and GATA2 expression, respectively, in a cohort of 236 patients. Cox proportional hazard regression and Kaplan-Meier survival analysis were performed to study the association between KRAS mutation or GATA2 expression and clinical outcomes. Kaplan-Meier analysis revealed that KRAS mutant patients with high expression of GATA2 had significantly worse long-term clinical outcomes than those with low expression of GATA2 (P<0.001). Further analysis showed that patients with both KRAS mutation and high GATA2 expression experienced significantly more unfavorable 5-year outcomes than patients with wild- type KRAS and low GATA2 expression (P=0.001). Univariate and multivariate Cox proportional hazard regression demonstrated the GATA2 expression level was an independent risk factor for overall survival of CRC patients (HR 1.645; 95% CI 1.004-2.696; P=0.048). In conclusion, the results of this study demonstrated that high expression of GATA2 is correlated with worse survival outcomes in KRAS mutant CRC patients, suggesting that GATA2 may serve as a novel biomarker for the survival of CRC patients harboring KRAS mutation.

View Figures

View References

1	DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS and Jemal A: Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 64:252–271. 2014. View Article : Google Scholar : PubMed/NCBI
2	Siegel R, Desantis C and Jemal A: Colorectal cancer statistics, 2014. CA Cancer J Clin. 64:104–117. 2014. View Article : Google Scholar : PubMed/NCBI
3	Ahmed S, Johnson K, Ahmed O and Iqbal N: Advances in the management of colorectal cancer: From biology to treatment. Int J Colorectal Dis. 29:1031–1042. 2014. View Article : Google Scholar : PubMed/NCBI
4	De Rosa M, Pace U, Rega D, Costabile V, Duraturo F, Izzo P and Delrio P: Genetics, diagnosis and management of colorectal cancer (Review). Oncol Rep. 34:1087–1096. 2015.PubMed/NCBI
5	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
6	Macedo MP, Andrade LB, Coudry R, Crespo R, Gomes M, Lisboa BC, Aguiar S Jr, Soares FA, Carraro DM and Cunha IW: Multiple mutations in the Kras gene in colorectal cancer: Review of the literature with two case reports. Int J Colorectal Dis. 26:1241–1248. 2011. View Article : Google Scholar : PubMed/NCBI
7	Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, et al: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 359:1757–1765. 2008. View Article : Google Scholar : PubMed/NCBI
8	Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, et al: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 26:1626–1634. 2008. View Article : Google Scholar : PubMed/NCBI
9	De Roock W, De Vriendt V, Normanno N, Ciardiello F and Tejpar S: KRAS, BRAF, PIK3CA, and PTEN mutations: Implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol. 12:594–603. 2011. View Article : Google Scholar
10	Inoue Y, Saigusa S, Iwata T, Okugawa Y, Toiyama Y, Tanaka K, Uchida K, Mohri Y and Kusunoki M: The prognostic value of KRAS mutations in patients with colorectal cancer. Oncol Rep. 28:1579–1584. 2012.PubMed/NCBI
11	Arrington AK, Heinrich EL, Lee W, Duldulao M, Patel S, Sanchez J, Garcia-Aguilar J and Kim J: Prognostic and predictive roles of KRAS mutation in colorectal cancer. Int J Mol Sci. 13:12153–12168. 2012. View Article : Google Scholar : PubMed/NCBI
12	Kadowaki S, Kakuta M, Takahashi S, Takahashi A, Arai Y, Nishimura Y, Yatsuoka T, Ooki A, Yamaguchi K, Matsuo K, et al: Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer. World J Gastroenterol. 21:1275–1283. 2015. View Article : Google Scholar : PubMed/NCBI
13	Sameen S, Barbuti R, Milazzo P, Cerone A, Del Re M and Danesi R: Mathematical modeling of drug resistance due to KRAS mutation in colorectal cancer. J Theor Biol. 389:263–273. 2016. View Article : Google Scholar
14	Collin M, Dickinson R and Bigley V: Haematopoietic and immune defects associated with GATA2 mutation. Br J Haematol. 169:173–187. 2015. View Article : Google Scholar : PubMed/NCBI
15	Tsai FY and Orkin SH: Transcription factor GATA-2 is required for proliferation/survival of early hematopoietic cells and mast cell formation, but not for erythroid and myeloid terminal differentiation. Blood. 89:3636–3643. 1997.PubMed/NCBI
16	Ohmori S, Moriguchi T, Noguchi Y, Ikeda M, Kobayashi K, Tomaru N, Ishijima Y, Ohneda O, Yamamoto M and Ohneda K: GATA2 is critical for the maintenance of cellular identity in differentiated mast cells derived from mouse bone marrow. Blood. 125:3306–3315. 2015. View Article : Google Scholar : PubMed/NCBI
17	Nandakumar SK, Johnson K, Throm SL, Pestina TI, Neale G and Persons DA: Low-level GATA2 overexpression promotes myeloid progenitor self-renewal and blocks lymphoid differentiation in mice. Exp Hematol. 43:565–577. e1–10. 2015. View Article : Google Scholar : PubMed/NCBI
18	Hsu AP, McReynolds LJ and Holland SM: GATA2 deficiency. Curr Opin Allergy Clin Immunol. 15:104–109. 2015. View Article : Google Scholar :
19	Vicente C, Conchillo A, García-Sánchez MA and Odero MD: The role of the GATA2 transcription factor in normal and malignant hematopoiesis. Crit Rev Oncol Hematol. 82:1–17. 2012. View Article : Google Scholar
20	Wang Y, He X, Ngeow J and Eng C: GATA2 negatively regulates PTEN by preventing nuclear translocation of androgen receptor and by androgen-independent suppression of PTEN transcription in breast cancer. Hum Mol Genet. 21:569–576. 2012. View Article : Google Scholar
21	Vidal SJ, Rodriguez-Bravo V, Quinn SA, Rodriguez-Barrueco R, Lujambio A, Williams E, Sun X, de la Iglesia-Vicente J, Lee A, Readhead B, et al: A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer. Cancer Cell. 27:223–239. 2015. View Article : Google Scholar : PubMed/NCBI
22	Wu D, Sunkel B, Chen Z, Liu X, Ye Z, Li Q, Grenade C, Ke J, Zhang C, Chen H, et al: Three-tiered role of the pioneer factor GATA2 in promoting androgen-dependent gene expression in prostate cancer. Nucleic Acids Res. 42:3607–3622. 2014. View Article : Google Scholar : PubMed/NCBI
23	Chen L, Jiang B, Wang Z, Liu M, Ma Y, Yang H, Xing J, Zhang C, Yao Z, Zhang N, et al: Expression and prognostic significance of GATA-binding protein 2 in colorectal cancer. Med Oncol. 30:4982013. View Article : Google Scholar : PubMed/NCBI
24	Kumar MS, Hancock DC, Molina-Arcas M, Steckel M, East P, Diefenbacher M, Armenteros-Monterroso E, Lassailly F, Matthews N, Nye E, et al: The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell. 149:642–655. 2012. View Article : Google Scholar : PubMed/NCBI
25	Shen S, Mao CQ, Yang XZ, Du XJ, Liu Y, Zhu YH and Wang J: Cationic lipid-assisted polymeric nanoparticle mediated GATA2 siRNA delivery for synthetic lethal therapy of KRAS mutant non-small-cell lung carcinoma. Mol Pharm. 11:2612–2622. 2014. View Article : Google Scholar : PubMed/NCBI
26	Gao J, Li YY, Sun PN and Shen L: Comparative analysis of dideoxy sequencing, the KRAS StripAssay and pyrosequencing for detection of KRAS mutation. World J Gastroenterol. 16:4858–4864. 2010. View Article : Google Scholar : PubMed/NCBI
27	Xing X, Peng L, Qu L, Ren T, Dong B, Su X and Shou C: Prognostic value of PRL-3 overexpression in early stages of colonic cancer. Histopathology. 54:309–318. 2009. View Article : Google Scholar : PubMed/NCBI
28	Ayanbule F, Belaguli NS and Berger DH: GATA factors in gastrointestinal malignancy. World J Surg. 35:1757–1765. 2011. View Article : Google Scholar : PubMed/NCBI
29	Peters I, Dubrowinskaja N, Tezval H, Kramer MW, von Klot CA, Hennenlotter J, Stenzl A, Scherer R, Kuczyk MA and Serth J: Decreased mRNA expression of GATA1 and GATA2 is associated with tumor aggressiveness and poor outcome in clear cell renal cell carcinoma. Target Oncol. 10:267–275. 2015. View Article : Google Scholar
30	Li YW, Wang JX, Yin X, Qiu SJ, Wu H, Liao R, Yi Y, Xiao YS, Zhou J, Zhang BH, et al: Decreased expression of GATA2 promoted proliferation, migration and invasion of HepG2 in vitro and correlated with poor prognosis of hepatocellular carcinoma. PLoS One. 9:e875052014. View Article : Google Scholar : PubMed/NCBI
31	Tessema M, Yingling CM, Snider AM, Do K, Juri DE, Picchi MA, Zhang X, Liu Y, Leng S, Tellez CS, et al: GATA2 is epigenetically repressed in human and mouse lung tumors and is not requisite for survival of KRAS mutant lung cancer. J Thorac Oncol. 9:784–793. 2014. View Article : Google Scholar : PubMed/NCBI
32	Darnell JE Jr: Transcription factors as targets for cancer therapy. Nat Rev Cancer. 2:740–749. 2002. View Article : Google Scholar : PubMed/NCBI
33	Kim SE, Paik HY, Yoon H, Lee JE, Kim N and Sung MK: Sex- and gender-specific disparities in colorectal cancer risk. World J Gastroenterol. 21:5167–5175. 2015. View Article : Google Scholar : PubMed/NCBI